Clinical Trials Logo

Filter by:
NCT ID: NCT03177421 Terminated - Clinical trials for Sleep Hygiene, Inadequate

Health Information Technology to Improve Bedtime Media Use in Children

Start date: June 13, 2017
Phase: N/A
Study type: Interventional

The objective of this study is to use health information technology to implement and evaluate a counseling recommendation for children who suffer from problematic sleep associated with bedtime media use. Participants will be randomized by clinic to be screened for basic sleep concerns and receive appropriate counseling, or to be screened for sleep concerns and media use, and receive appropriate counseling.

NCT ID: NCT03176394 Terminated - Clinical trials for Urinary Tract Infections

Efficacy of BLASTX in Catheter Associated Bacteriuria Versus Standard of Care (SOC)

Start date: May 24, 2017
Phase: N/A
Study type: Interventional

This is a 2-week, single-site, randomized study in adults requiring short-term (≤ 14 days) catheterization. Subjects will be randomized 1:1 to either the biofilm disrupting gel (BLASTX) or SOC (McKesson Jelly) lubricated catheters. Urine and/or catheter DNA analysis will be obtained at catheter insertion, 2, 5, 7 and 14 days after catheterization.

NCT ID: NCT03176277 Terminated - Clinical trials for Myelodysplastic Syndromes

A Study of ONO-7475 in Patients With Acute Leukemias

Start date: June 26, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

[Updated]: To assess the safety and tolerability of ONO-7475 monotherapy in patients with relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes and to assess: i) safety and tolerability and ii) preliminary efficacy of the combination of ONO-7475 and venetoclax in patients with relapsed or refractory acute myeloid leukemia.

NCT ID: NCT03175978 Terminated - Clinical trials for Myelodysplastic Syndromes

IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

Start date: February 21, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to determine the safety and tolerability of utilizing the insulin-like growth factor-1-methotrexate conjugate, 765IGF-MTX for the treatment of advanced, previously treated myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and oligoblastic acute myelogenous leukemia (oligoblastic AML or O-AML), including determining the maximum tolerated dose (MTD).

NCT ID: NCT03175172 Terminated - Clinical trials for Malignant Pleural Mesothelioma

Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)

Start date: May 31, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate whether CRS-207 with pembrolizumab is safe and effective in adults with MPM who have failed prior anti-cancer therapy.

NCT ID: NCT03174808 Terminated - Anxiety Clinical Trials

Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)

Start date: August 20, 2017
Phase: N/A
Study type: Interventional

The primary objective is to assess the feasibly, adherence, and effects of mindfulness-based stress reduction (MBSR) on anxiety and health-related quality of life in adult patients with cutaneous T-cell lymphoma at the Yale Cancer Center/Smilow Cancer Hospital. Participants will attend group sessions led by an instructor experienced in MBSR in an academic setting. The mindfulness meditation group sessions will take place at the Smilow Cancer Center at the Yale New-Haven Hospital.

NCT ID: NCT03174782 Terminated - Postoperative Pain Clinical Trials

Peripheral Nerve Blocks for Major Lower Extremity Amputations

Start date: January 1, 2018
Phase: Phase 4
Study type: Interventional

This study will be a double-blinded randomized controlled trial analyzing all patients who will undergo major lower extremity amputations by the vascular surgery service at University of California, San Francisco (UCSF) Fresno between July 2017 and June 2018 to determine if regional nerve blocks (sciatic and femoral) have any effect on postoperative pain control, narcotic requirements, and length of stay compared with standard post-operative narcotic regimens.

NCT ID: NCT03173430 Terminated - Multiple Myeloma Clinical Trials

Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma

Start date: May 27, 2017
Phase: Early Phase 1
Study type: Interventional

This study involves receiving blinatumomab after high-dose melphalan and ASCT for multiple myeloma. The main purpose of this study is to: - To determine whether blinatumomab is safe and feasible to administer after ASCT in patients with advanced multiple myeloma. - To assess how long multiple myeloma remains under control when blinatumomab is administered after second ASCT.

NCT ID: NCT03173326 Terminated - General Anesthesia Clinical Trials

Patient Satisfaction and Postoperative Analgesia Between Subarachnoid Block With 2-chloroprocaine Versus General Anesthesia for Knee Arthroscopy

Start date: June 16, 2017
Phase: N/A
Study type: Interventional

The study evaluates the efficacy of two different anesthetic techniques in patients undergoing unilateral knee arthroscopy. Participants will be randomized to receive either subarachnoid block with 2-chloroprocaine or general anesthesia plus intravenous fentanyl.

NCT ID: NCT03173274 Terminated - Nicotine Dependence Clinical Trials

Incentives to Promote Smoking Cessation in Low SES Women

ProjectMIST
Start date: February 8, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the feasibility of a mobile-phone based contingency management (CM) intervention for smoking in low-SES women. The CM intervention will be combined with a Brief Motivational Interviewing (BMI) counseling component. This study will examine the following research aims: Primary Aim: To compare the effects of a Brief Motivational Intervention (BMI) + mobile phone-based CM on tobacco use when compared to BMI with a non-contingent control condition in a small feasibility trial. Hypothesis: The investigators expect women in the BMI + CM condition to have more smoke free days than women in the BMI + NC condition. Secondary Aim: To examine alcohol use as a moderator of cessation outcomes.